These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14698197)

  • 1. 7-Hydroxynaphthalen-1-yl-urea and -amide antagonists of human vanilloid receptor 1.
    McDonnell ME; Zhang SP; Nasser N; Dubin AE; Dax SL
    Bioorg Med Chem Lett; 2004 Jan; 14(2):531-4. PubMed ID: 14698197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-isoquinolin-5-yl-N'-aralkyl-urea and -amide antagonists of human vanilloid receptor 1.
    Jetter MC; Youngman MA; McNally JJ; Zhang SP; Dubin AE; Nasser N; Dax SL
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3053-6. PubMed ID: 15149643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.
    Tafesse L; Sun Q; Schmid L; Valenzano KJ; Rotshteyn Y; Su X; Kyle DJ
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5513-9. PubMed ID: 15482915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of potent selective NPY Y(2) antagonists.
    Chai W; Wong VD; Nepomuceno D; Bonaventure P; Lovenberg TW; Carruthers NI
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4141-4. PubMed ID: 23756063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
    Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).
    Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3416-20. PubMed ID: 23591110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists.
    Sun W; Kim HS; Lee S; Jung A; Kim SE; Ann J; Yoon S; Choi S; Lee JH; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Schiene K; Stockhausen H; Christoph T; Frormann S; Lee J
    Bioorg Med Chem Lett; 2015 Feb; 25(4):803-6. PubMed ID: 25597011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
    Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
    J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of small molecule antagonists of TRPV1.
    Rami HK; Thompson M; Wyman P; Jerman JC; Egerton J; Brough S; Stevens AJ; Randall AD; Smart D; Gunthorpe MJ; Davis JB
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3631-4. PubMed ID: 15203132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist.
    Wahl P; Foged C; Tullin S; Thomsen C
    Mol Pharmacol; 2001 Jan; 59(1):9-15. PubMed ID: 11125018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.
    Swanson DM; Dubin AE; Shah C; Nasser N; Chang L; Dax SL; Jetter M; Breitenbucher JG; Liu C; Mazur C; Lord B; Gonzales L; Hoey K; Rizzolio M; Bogenstaetter M; Codd EE; Lee DH; Zhang SP; Chaplan SR; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):1857-72. PubMed ID: 15771431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
    Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
    J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRPV3 is a temperature-sensitive vanilloid receptor-like protein.
    Smith GD; Gunthorpe MJ; Kelsell RE; Hayes PD; Reilly P; Facer P; Wright JE; Jerman JC; Walhin JP; Ooi L; Egerton J; Charles KJ; Smart D; Randall AD; Anand P; Davis JB
    Nature; 2002 Jul; 418(6894):186-90. PubMed ID: 12077606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Aminophenyl acetamides and propanamides as potent transient receptor potential vanilloid 1 (TRPV1) ligands.
    Kim C; Ann J; Lee S; Kim E; Choi S; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Stockhausen H; Christoph T; Lee J
    Bioorg Med Chem; 2018 Aug; 26(15):4509-4517. PubMed ID: 30078610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
    Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3421-6. PubMed ID: 23591112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands.
    Park HG; Choi JY; Kim MH; Choi SH; Park MK; Lee J; Suh YG; Cho H; Oh U; Kim HD; Joo YH; Shin SS; Kim JK; Jeong YS; Koh HJ; Park YH; Jew SS
    Bioorg Med Chem Lett; 2005 Feb; 15(3):631-4. PubMed ID: 15664827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development.
    Rami HK; Thompson M; Stemp G; Fell S; Jerman JC; Stevens AJ; Smart D; Sargent B; Sanderson D; Randall AD; Gunthorpe MJ; Davis JB
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3287-91. PubMed ID: 16580202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of piperidine carboxamide TRPV1 antagonists.
    Cheung WS; Calvo RR; Tounge BA; Zhang SP; Stone DR; Brandt MR; Hutchinson T; Flores CM; Player MR
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4569-72. PubMed ID: 18662879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
    Valenzano KJ; Grant ER; Wu G; Hachicha M; Schmid L; Tafesse L; Sun Q; Rotshteyn Y; Francis J; Limberis J; Malik S; Whittemore ER; Hodges D
    J Pharmacol Exp Ther; 2003 Jul; 306(1):377-86. PubMed ID: 12721338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor population.
    Tóth A; Blumberg PM; Chen Z; Kozikowski AP
    Mol Pharmacol; 2004 Feb; 65(2):282-91. PubMed ID: 14742669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.